DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, November 8, 2018 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2018, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 4646308. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.